Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Ziconotide (Prialt)25 residuesCKGKGAKCSRLMYDCCTGSCRSGKCEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Prialt, omega-conotoxin MVIIA, SNX-111
A cone snail venom turned FDA-approved painkiller. Ziconotide (brand name Prialt) is a synthetic 25-amino-acid copy of omega-conotoxin MVIIA, approved in December 2004 for severe chronic pain that nothing else can touch. It blocks N-type calcium channels (Cav2.2) at the spinal cord level, stopping pain signals without binding a single opioid receptor. No tolerance builds over years of continuous use; a 2025 meta-analysis of 23 studies (n=1,531) confirmed a mean pain reduction of 22.54 points versus placebo. The catch is delivery. Ziconotide requires continuous intrathecal infusion through a surgically implanted pump, and psychiatric side effects forced discontinuation in roughly half of real-world patients within two years.
A 2025 meta-analysis pooling 23 studies and 1,531 patients landed on a mean pain reduction of 22.54 points versus placebo (p=0.002)[1]. That is the most current aggregate number for ziconotide, an FDA-approved peptide derived from Pacific cone snail venom. Ziconotide (Prialt, omega-conotoxin MVIIA, CAS 107452-89-1) is a synthetic 25-amino-acid peptide with three disulfide bonds. The FDA approved it in December 2004 for severe chronic pain in patients who have failed or cannot tolerate other analgesic options, including intrathecal morphine. The mechanism is selective Cav2.2 calcium channel blockade at the spinal cord dorsal horn. By physically occluding these channels on nociceptive nerve terminals, ziconotide prevents release of glutamate, CGRP, and substance P. Pain signals stop before reaching the brain. No opioid receptors are involved, so respiratory depression and tolerance are absent. Three important RCTs built the approval case. Study 96-002 (Wallace et al.)[2] showed 31.2% mean pain reduction versus 6.0% for placebo in 255 patients. Study 301 (Rauck et al.)[3] confirmed efficacy with slower titration in 220 patients. A long-term open-label extension tracked 644 patients over 350 patient-years of sustained relief (Wallace et al.)[4]. Real-world outcomes tell a more complicated story. The PRIZM registry (n=93) recorded about 50% of patients achieving 30% or greater pain reduction at 12 months. Psychiatric side effects, including hallucinations (12%), psychosis (1%), and insidious cognitive decline, drove high discontinuation rates. Only about 4 of 15 patients remained on therapy at two years in one cohort. The 2024 PACC guidelines now recommend starting at 0.5 to 1.0 mcg/day, well below the FDA label's 2.4 mcg/day, because slower titration dramatically reduces CNS adverse events.
Three disulfide bonds lock ziconotide into a rigid three-dimensional structure. That shape is what makes it fit the Cav2.2 calcium channel pore like a plug. The peptide binds the extracellular surface of the alpha-1B subunit and physically blocks calcium ions from flowing through. Cav2.2 channels sit densely on nociceptive nerve terminals in laminae I and II of the spinal cord dorsal horn. When calcium can't enter those terminals, vesicular release of excitatory neurotransmitters stops. Glutamate, CGRP, and substance P all stay locked in their presynaptic vesicles. The first central synapse in the pain pathway goes quiet. Selectivity is the pharmacological headline. Ziconotide has zero affinity for mu, delta, or kappa opioid receptors. It also ignores adrenergic, serotonin, dopamine, and GABA receptors. This explains why opioid side effects (respiratory depression, constipation, escalating tolerance) simply don't occur. There is no receptor downregulation or compensatory upregulation pathway with Cav2.2 blockade; tolerance does not develop over months or years. The same Cav2.2 channels also exist in supraspinal brain regions that regulate cognition, mood, and motor function. Blocking them there produces the dose-limiting neuropsychiatric toxicity: confusion, hallucinations, memory impairment, and psychosis. That overlap between therapeutic target and toxicity target creates the narrow therapeutic window that makes ziconotide so difficult to dose.
FDA-approved (2004) for severe refractory chronic pain via continuous intrathecal infusion. Three pivotal RCTs established efficacy. 2025 meta-analysis (n=1,531, 23 studies) confirmed mean pain reduction of −22.54 points vs placebo (p=0.002). No pharmacological tolerance. Serious AE rate 17.85% (2.63× placebo). Confined to tertiary pain management settings requiring surgical pump implantation.
Gater et al. Pain Rep 2025 (PMID 41255849): meta-analysis 23 studies n=1,531; also SPIDOL RCT protocol (Trials 2024, PMID 39244617) for SCI neuropathic pain.
Pivotal RCTs used faster titration than current clinical best practice; high AE-driven dropout rates inflate discontinuation figures; intrathecal-only delivery severely limits applicability; real-world PRIZM registry shows ~50% ≥30% responder rate at 12 months, lower than RCT estimates.
Mixed-to-negative overall sentiment (Drugs.com 4.3/10, 27% positive, 45% negative). Those who tolerate it describe meaningful, sustained relief. Most negative reports center on severe CNS adverse effects. High real-world discontinuation: only ~4/15 patients still on drug at 2 years in one cohort.
Both science and community confirm analgesic efficacy for refractory pain. Divergence on tolerability: clinical trials underestimate real-world CNS AE burden and discontinuation rates. The 2024 PACC guideline shift to 0.5 mcg/day starting dose (vs. FDA label 2.4 mcg/day) reflects this community-driven understanding that slower titration dramatically improves real-world tolerability.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2.4mcg | Daily |
| Moderate | 9.6mcg | Daily |
| Aggressive | 19.2mcg | Daily |
Ziconotide ships as a pre-filled solution, not a lyophilized powder. No reconstitution with bacteriostatic water is needed. The two concentrations are 25 mcg/mL and 100 mcg/mL. Delivery math for the 25 mcg/mL formulation in a 20 mL vial: 500 mcg total per vial. At a maintenance dose of 5 mcg/day, that is a 100-day supply per pump refill. The 100 mcg/mL concentration must be diluted with preservative-free normal saline (not bacteriostatic water) when used in external pumps. The FDA label says you can start at 2.4 mcg/day. Most pain specialists don't anymore. The 2024 PACC consensus guidelines recommend 0.5 to 1.0 mcg/day with increases no larger than 0.5 mcg/day per week. That slower ramp cuts psychiatric and cognitive side effects dramatically compared to the FDA-label titration speed. Your pump refill schedule depends on concentration, flow rate, and reservoir size. Typical intervals run every 1 to 3 months. Every refill visit should include cognitive screening, psychiatric assessment, orthostatic blood pressure, and CK levels.
Ziconotide is used as continuous long-term therapy delivered via intrathecal pump, not cycled. Treatment is maintained indefinitely as long as the patient derives analgesic benefit and tolerates the medication. Dose adjustments are made gradually: no more than 2.4 mcg/day increases, no more frequently than 2-3 times per week. If discontinued, no taper is required as there is no physical dependence or withdrawal syndrome. Treatment may be interrupted or discontinued if psychiatric symptoms, cognitive impairment, or elevated CK levels occur.
No cycling protocol is used. Ziconotide acts via direct Cav2.2 calcium channel occlusion with no receptor internalization, downregulation, or compensatory upregulation pathway: pharmacological tolerance does not develop. Treatment is continuous and indefinite. Dose adjustments (reductions) manage side effects; abrupt discontinuation is safe if required (no withdrawal syndrome). No on/off cycling confers any clinical benefit.
Or use the universal Peptide Calculator for any peptide.
Expected: ≥30% pain reduction in ~50% of patients at 12 months (PRIZM real-world); −22.54 mean VAS/NRS reduction vs placebo in meta-analysis; 31.2% mean pain reduction in pivotal Study 96-002 (rapid titration arm)
Monitor: CK every 2 weeks for first month, then monthly. MMSE or MoCA at every visit (baseline required). Psychiatric assessment each visit. Orthostatic BP at each pump refill.
Ziconotide requires a Medtronic SynchroMed II implantable intrathecal pump or an external microinfusion device with intrathecal catheter. This is not a subcutaneous, intravenous, or epidural medication.
A qualified healthcare provider fills the pump reservoir under strict sterile conditions. The 25 mcg/mL solution can go in undiluted. The 100 mcg/mL solution gets diluted with preservative-free 0.9% NaCl to the target concentration.
Starting dose is 0.5 to 1.0 mcg/day per 2024 PACC guidelines (or up to 2.4 mcg/day per the FDA label). The pump delivers this continuously over 24 hours, not as a bolus. At 1.0 mcg/day, the pump flow rate is approximately 0.042 mcg/hour.
Titration: increase by no more than 0.5 mcg/day per week (PACC preferred) or 2.4 mcg/day no more than 2 to 3 times per week (FDA maximum titration rate). Each dose adjustment requires a clinical visit.
Most patients find an effective maintenance dose between 2 and 9.6 mcg/day; the PRIZM registry median landed around 5.5 to 7.2 mcg/day.
Monitoring at every visit: MMSE or MoCA for cognitive function, psychiatric screening, orthostatic blood pressure. CK levels every 2 weeks for the first month, then monthly. Any new psychiatric symptom triggers a dose hold.
Undiluted vials can sit at room temperature (up to 25 degrees Celsius) for up to 14 days. Once in the pump, use within 84 days refrigerated or 40 days at body temperature.
Most studied IT combination with ziconotide; complementary mechanisms (opioid + Cav2.2 blockade); used off-label for refractory cancer and non-cancer pain. Admixture stability confirmed up to ~20 days.
Combination IT pump; individual doses titrated independently. Admixture prepared by pharmacy.
Complementary mechanism (alpha-2 adrenergic); good admixture stability (~90% at 60 days at clonidine 2 mcg/mL + ziconotide). Preferred combination for neuropathic pain per PACC.
Clonidine 2 mcg/mL + ziconotide in combination IT pump; monitor for additive hypotension.
Alternative to morphine for opioid-intolerant patients; case reports in spinal cord injury neuropathic pain (PMID 17310258).
Additive CNS depression: increased dizziness, confusion, somnolence. FDA-labeled drug interaction.
Increased risk of psychiatric AEs and depressed consciousness when combined with ziconotide. FDA-labeled interaction.
Patients on diuretics are at higher risk of depressed level of consciousness per FDA label.
Confound mandatory CK monitoring; may amplify rhabdomyolysis risk signal. Use with caution and increased CK monitoring frequency.
Pricing updated 2026-04-09
Black Box Warning: severe psychiatric symptoms and neurological impairment. This is the lead safety concern, not a footnote. Hallucinations hit 12% of trial patients. Psychosis occurred in 1%. Depression with suicidal ideation has been reported. Documented cases of psychiatric recurrence on rechallenge exist [5], meaning once ziconotide triggers psychosis, restarting it is not safe. Cognitive impairment is the most insidious problem. Word-finding difficulty, memory loss, and confusion affected 7 to 22% of patients in clinical trials. The onset can be gradual enough that patients or families don't recognize the decline for weeks. Formal cognitive screening (MMSE or MoCA) at every visit catches what casual conversation misses. Any new cognitive symptom within weeks of a dose increase should be attributed to ziconotide until proven otherwise. Dizziness was the single most common adverse event at 47%. Nausea reached 30%. Confusion hit 33%. Somnolence affected 22%. Abnormal gait (14%), nystagmus (8%), and visual disturbances also appeared in important trials. Most of these track directly with dose; slower titration per the 2024 PACC guidelines (0.5 mcg/day increases weekly instead of the FDA-label rate) substantially reduces incidence. CK elevation occurred in 10 to 40% of patients. Levels above 3 times the upper limit of normal require dose reduction or hold. Investigate for rhabdomyolysis symptoms (dark urine, muscle pain) if CK spikes. Meningitis, both chemical and bacterial, has been reported in patients using external microinfusion devices. Strict aseptic technique during pump refills is non-negotiable. Postural hypotension, urinary retention, fever, and asthenia round out the profile. The serious adverse event rate across the meta-analysis was 17.85%, roughly 2.6 times the placebo rate. Contraindications: preexisting psychosis (FDA-labeled), active suicidal ideation, severe untreated depression, spinal canal obstruction, uncontrolled bleeding diathesis, active infection at the pump site, pregnancy (Category C), and breastfeeding. When to seek immediate medical attention: new hallucinations, suicidal thoughts, sudden cognitive decline, high-grade fever with neck stiffness, or dark urine with muscle pain.
Verify Ziconotide (Prialt) dosing and safety with a second opinion
FDA-approved pharmaceutical product (Prialt, TerSera Therapeutics). No research-grade, compounded, or gray-market versions exist. Standard pharmaceutical supply chain under hospital/specialty pharmacy controls. Product quality is not a sourcing risk: clinical adverse effects are the dominant risk.
| Test | When | Target |
|---|---|---|
| Creatine Kinase (CK / CPK) | Every 2 weeks for first month; monthly thereafter | <3× ULN; reduce or hold dose if >3× ULN; investigate clinically for rhabdomyolysis symptoms |
| Cognitive Assessment (MMSE or MoCA) | Baseline before initiation required; every clinical visit during titration and maintenance | Significant decline from individual baseline warrants dose reduction or discontinuation |
| Psychiatric Evaluation | Baseline (mandatory: psychosis is FDA contraindication); every visit; urgently with any new psychiatric symptom | Any new hallucinations, psychosis, or suicidal ideation → dose reduction or discontinuation |
| Blood Pressure (orthostatic) | Each pump refill visit | — |
| CSF Analysis | If fever, headache, or neck stiffness develop: especially in patients with external pump | — |
Rhabdomyolysis risk documented in clinical trials; CK elevation common (10–40% of patients)
Ziconotide-induced cognitive impairment can be insidious; formal baseline enables objective comparison
Black Box Warning: hallucinations (12%), psychosis (1%), depression with suicidal ideation; symptoms can emerge weeks after dose change
Postural hypotension reported; additive risk if combined with IT clonidine, systemic diuretics, or antihypertensives
Chemical meningitis and bacterial meningitis both reported; external devices carry highest risk; requires urgent evaluation and lumbar puncture
Intrathecal infusion begins at 2.4 mcg/day (0.1 mcg/hour). Steady-state CSF concentration is approximated within ~24 hours (approximately five half-lives). Some patients may notice early pain relief within hours. Common initial side effects include dizziness, nausea, and somnolence.
Gradual dose escalation in increments of no more than 2.4 mcg/day, no more than 2-3 times per week. Pain relief increases with dose. Cognitive side effects (confusion, memory impairment) and psychiatric symptoms may emerge during this period: careful monitoring is essential.
Most patients reach an effective maintenance dose, typically between 4.8-14.4 mcg/day in clinical practice. In pivotal trials, mean effective doses ranged from 6.9-9.6 mcg/day. CK levels should be monitored every other week.
Sustained analgesia at stable dose. Unlike opioids, tolerance does not develop. Ongoing monitoring for insidious cognitive changes, mood disturbances, and psychiatric symptoms is critical. CK monitoring transitions to monthly.
Long-term maintenance with continued efficacy. Pump refills every 1-3 months depending on concentration and flow rate. Long-term open-label data shows sustained pain relief over 350+ patient-years. Periodic neuropsychological assessment is recommended.
Day 1 to 7 (Initiation): Intrathecal infusion starts at 0.5 to 2.4 mcg/day depending on protocol. CSF steady-state concentration arrives within roughly 24 hours (about five half-lives at 4.6 hours CSF t1/2). Some patients notice partial pain relief within hours. Dizziness (47% in trials), nausea (30%), and somnolence (22%) are the dominant early side effects. Most side effect tolerance improves within the first week. Weeks 1 to 8 (Titration): Dose climbs in incremental steps. PACC slow titration (0.5 mcg/day increases weekly) is preferred in clinical practice over the faster FDA-label schedule. Psychiatric and cognitive adverse events are most likely to surface or worsen during active escalation. Fast titration produced 53.1% pain reduction in trials but carried very high side effect burden. Community and clinical experience consistently favor the slower approach. Confusion (33%), memory impairment (7 to 22%), nystagmus (8%), abnormal gait (14%), and visual changes are the main concerns during this phase. Months 2 to 6 (Stabilization): Most patients reach an effective maintenance dose, typically between 2 and 9.6 mcg/day. The PRIZM registry recorded a median of 5.5 to 7.2 mcg/day in real-world use. No tolerance develops, so dose requirements stay stable indefinitely. High discontinuation occurs at this stage from delayed-onset cognitive impairment that patients or families only recognize retrospectively. PRIZM data showed about 50% of patients achieving 30% or greater pain relief at month 12. Months 6 to 24 and beyond (Long-term Maintenance): Sustained pain relief without dose escalation is the defining advantage over intrathecal opioids. The open-label extension (n=644) confirmed continued efficacy over 350 patient-years. Pump refills run every 1 to 3 months. Long-term users describe it as transformative for refractory pain but acknowledge cognitive costs at higher doses. Real-world attrition is steep; roughly 4 of 15 patients remained on therapy at two years in one cohort. External pump users face ongoing meningitis risk from both chemical and bacterial sources.
CSF steady-state achieved within ~24 hours (~5 half-lives at 4.6 hr CSF t½). Some patients report early partial pain relief within hours.
Mixed first impressions: some notice relief quickly; many experience prominent side effects (dizziness, nausea, sedation) before meaningful pain benefit. Tolerance to side effects often improves within first week.
Incremental pain reduction with each dose step. Psychiatric and cognitive AEs most likely to emerge or worsen during active titration. Fast titration (FDA-label rate) associated with 53.1% pain reduction but very high AE burden.
PACC slow titration (≤0.5 mcg/day/week) consistently preferred in clinical practice. Patients on rapid titration report high rates of cognitive "fog" and psychiatric symptoms. Many discontinue during this phase.
Most patients reach effective maintenance dose (2–9.6 mcg/day in trials; 2–7 mcg/day real-world). No tolerance development: dose requirements stable indefinitely.
Those who tolerate it report meaningful sustained relief. High discontinuation at this stage due to delayed-onset cognitive impairment that patients or families recognize only retrospectively. PRIZM registry: 50% ≥30% responders at Month 12.
Sustained efficacy without dose escalation: key advantage over intrathecal opioids. Long-term OLE (n=644, 350+ patient-years) confirms continued pain relief. Pump refills every 1–3 months.
Long-term survivors describe it as life-changing for refractory pain but acknowledge significant cognitive cost at higher doses. Real-world attrition: ~4/15 patients still on drug at 2 years in one cohort. External pump users face ongoing meningitis risk.
Source: FDA prescribing information; Wermeling D et al. J Clin Pharmacol. 2003;43(6):624-36. PMID: 12817525 (median 4.5 h in CSF, range 2.9-6.5 h)
Loading the interactive decay curve.
Ziconotide (Prialt) received FDA approval in December 2004 for the management of severe chronic pain in adult patients who require intrathecal therapy and have failed other treatments. It remains the only FDA-approved selective N-type calcium channel blocker for pain. TerSera Therapeutics currently markets it in the United States. This is a prescription medication, not a research peptide. No compounded or gray-market versions exist. All supply runs through standard pharmaceutical distribution under hospital and specialty pharmacy controls. Ziconotide carries a Black Box Warning for psychiatric symptoms and neurological impairment. It is classified as a non-scheduled drug (not a controlled substance) because it has no abuse potential or opioid-like reinforcing effects. Athletes should note that peptide hormones appear on the WADA prohibited list. Ziconotide is not a hormone, but consult a sports medicine physician and verify current WADA status if competition testing applies. This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any medication.
Peptide Schedule Research TeamReviewed Apr 202610 Citations
